Glycine‐replaced epinecidin‐1 variant bestows better stability and stronger antimicrobial activity against a range of nosocomial pathogenic bacteria

Abstract

Epinecidin‐1 (epi‐1), an antimicrobial peptide first identified in marine grouper fish, has multifunctional bioactivities. The present study aims to improve its therapeutic potential via structural modifications that could enhance its antimicrobial activity and stability. To achieve it, we replaced glycine and the first histidine in the parent epi‐1 with lysine, which resulted in a peptide with a repeating KXXK motif and improved physiochemical properties related to antimicrobial activity. This modified peptide, referred to as glycine‐to‐lysine replaced‐epi‐1, also gained stability and a twofold increase in helical propensity. To produce the active peptide, overlap extension PCR was employed to generate the gene of GK‐epi‐1 via site‐directed mutagenesis, which was then cloned into the pET‐32a vector and expressed as a recombinant fusion protein in Escherichia coli C43 (DE3) strain. The recombinant protein was purified and digested with enterokinase to release the active peptide fragment, which was then evaluated for antimicrobial activity and stability. The lysine substitution led to an enhancement in broad‐spectrum antimicrobial activity against a wide range of nosocomial pathogenic bacteria.